Dr. Brockhoff, in analyzing the EU versus the North American type of model, it stood out to me that the countries you listed are much more vast. A lot of the challenges we have in Canada are with getting our product to market for processing and keeping it safe and disease-free, and that requires different sets of drugs.
For the committee's sake and for the analysts as we write this report, I'll note that I think a lot of people forget just how big a country Canada is, the kinds of challenges we've come across over the years and how the industry and our producers have stepped up. We've been a shining example for the rest of the world to follow, instead of trying to catch up to them and conform to them.
This is for Dr. Brockhoff, or for the Canadian Pork Council. What role does regulatory flexibility play in antimicrobial resistance, particularly in the agriculture sector? Also, should the committee make recommendations on regulatory flexibility in its report?
